☆ 4.7 Article

Association of Plasma Phosphorylated Tau With the Response to Neflamapimod Treatment in Patients With Dementia With Lewy Bodies

NEUROLOGY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Clinical Neurology

Cholinergic white matter pathways in dementia with Lewy bodies and Alzheimer's disease

Julia Schumacher et al.

Summary: Patients with dementia with Lewy bodies and Alzheimer's disease exhibited early degeneration of the cholinergic nucleus basalis of Meynert. However, it remains unknown how white matter projections between the nucleus basalis of Meynert and the cortex are affected in neurodegenerative diseases. This study utilized diffusion-weighted imaging to investigate the white matter pathways originating from the nucleus basalis of Meynert in patients with different cognitive conditions. The results demonstrated that the integrity of these pathways is associated with cognition and attention, and might serve as an early indicator for the risk of dementia conversion in individuals with mild cognitive impairment.

BRAIN (2022)

添加到收藏夹

Article Clinical Neurology

Association of Plasma p-tau181 and p-tau231 Concentrations With Cognitive Decline in Patients With Probable Dementia With Lewy Bodies

Maria C. Gonzalez et al.

Summary: The study suggests that plasma p-tau181 and p-tau231 levels may be cost-effective and accessible biomarkers for assessing cognitive decline in individuals with DLB.

JAMA NEUROLOGY (2022)

添加到收藏夹

Editorial Material Neurosciences

Disease-modifying pharmacological approaches to correcting basal forebrain cholinergic neuronal (BFCN) dysfunction and degeneration

John J. Alam et al.

NEUROPSYCHOPHARMACOLOGY (2022)

添加到收藏夹

Article Clinical Neurology

Longitudinal Tau Positron Emission Tomography in Dementia with Lewy Bodies

Qin Chen et al.

Summary: This study investigated the longitudinal rate of tau accumulation and its association with neurodegeneration and clinical disease progression in patients with dementia with Lewy bodies (DLB). The study found that DLB patients had a faster increase in flortaucipir SUVr compared to the control group, with increased accumulation rates in the lateral occipital and temporoparietal cortices. These increased rates of tau accumulation were associated with neurodegeneration and faster disease progression in DLB.

MOVEMENT DISORDERS (2022)

添加到收藏夹

Review Neurosciences

Basal Forebrain Impairment: Understanding the Mnemonic Function of the Septal Region Translates in Therapeutic Advances

Marian Tsanov

Summary: The basal forebrain is a key brain circuit involved in episodic memory formation, particularly in relation to septal cholinergic signaling. Recent research has shown that the septal region in the basal forebrain plays a significant role in processing locomotor, rewarding, and attentional stimuli, guiding new therapeutic strategies for basal forebrain impairment.

FRONTIERS IN NEURAL CIRCUITS (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Preclinical and randomized clinical evaluation of the p38α kinase inhibitor neflamapimod for basal forebrain cholinergic degeneration

Ying Jiang et al.

Summary: The study found that Rab5 is closely related to BFCN degeneration, and inhibiting Rab5 activity may be a method for treating related diseases. The use of neflamapimod reduced Rab5 activity, reversed endosomal pathology, and restored the number and morphology of BFCNs. The clinical trial in DLB patients showed that neflamapimod did not affect cognitive function, but there were improvements in functional mobility and dementia rating-scale, confirming its effect on BFCN function.

NATURE COMMUNICATIONS (2022)

添加到收藏夹

Article Clinical Neurology

Longitudinal atrophy in prodromal dementia with Lewy bodies points to cholinergic degeneration

Kejal Kantarci et al.

Summary: This study found that prodromal dementia with Lewy bodies is characterized by atrophy in the nucleus basalis of Meynert. Longitudinally, grey matter atrophy progresses in regions with significant cholinergic innervation, with accelerated rates of atrophy in patients who progress to dementia with Lewy bodies.

BRAIN COMMUNICATIONS (2022)

添加到收藏夹

Article Clinical Neurology

Plasma Phospho-Tau Identifies Alzheimer's Co-Pathology in Patients with Lewy Body Disease

Sara Hall et al.

Summary: This study investigated plasma phospho-tau217 and phospho-tau181 in 35 patients with Lewy body disease with dementia, finding correlations with CSF and tau-PET imaging, and predictive value for pathological status. Plasma phospho-tau may serve as a useful marker for Alzheimer's co-pathology in Lewy body disease with dementia.

MOVEMENT DISORDERS (2021)

添加到收藏夹

Article Clinical Neurology

Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease

Alexis Moscoso et al.

Summary: This study found that plasma p-tau181 could serve as a marker for predicting and monitoring neurodegeneration and cognitive decline, with greater AD specificity compared to plasma NfL, holding important implications for monitoring AD progression in clinical practice and treatment trials.

JAMA NEUROLOGY (2021)

添加到收藏夹

Article Clinical Neurology

Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231

Sherif Bayoumy et al.

Summary: The study demonstrated that all P-tau Simoa assays showed robust analytical performance and the P-tau181, P-tau217 Eli Lilly, and P-tau231 Gothenburg assays performed well clinically in differentiating AD from controls. The results obtained from these assays correlated strongly, indicating that P-tau isoforms can be measured accurately with high-sensitive Simoa assays.

ALZHEIMERS RESEARCH & THERAPY (2021)

添加到收藏夹

Article Clinical Neurology

Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer's disease

Cecile Tissot et al.

Summary: This study investigated the association of plasma pTau181 with neurodegeneration in aging and Alzheimer's disease. The results showed that higher levels of plasma pTau181 were correlated with neurodegeneration and could predict further brain atrophy. Plasma pTau181 may be a useful predictor of Alzheimer's disease-related neurodegeneration.

ALZHEIMERS RESEARCH & THERAPY (2021)

添加到收藏夹

Article Clinical Neurology

Plasma p-tau181 Level Predicts Neurodegeneration and Progression to Alzheimer's Dementia: A Longitudinal Study

Yan-Li Wang et al.

Summary: Plasma p-tau181 levels are associated with multiple AD-associated cognitive domains and AD-related CSF biomarkers at the clinical stages of AD. Additionally, plasma p-tau181 levels are related to the change rates of cognitive decline and hippocampal atrophy. This study confirms the utility of plasma p-tau181 as a non-invasive biomarker for early detection and prediction of AD.

FRONTIERS IN NEUROLOGY (2021)

添加到收藏夹

Article Health Care Sciences & Services

Optimizing Cognitive Assessment Outcome Measures for Alzheimer's Disease by Matching Wordlist Memory Test Features to Scoring Methodology

Jason R. Bock et al.

Summary: Cognitive assessment with wordlist memory tests is a cost-effective method, but traditional scoring methods lack accuracy for subtle cognitive changes. Therefore, there is a need to develop more precise scoring methods to capture the information provided by these tests.

FRONTIERS IN DIGITAL HEALTH (2021)

添加到收藏夹

Article Neuroimaging

In vivo nucleus basalis of Meynert degeneration in mild cognitive impairment with Lewy bodies

Julia Schumacher et al.

Summary: The study found that cholinergic degeneration in the MCI-LB stage is related to cognitive impairment severity. Early EEG slowing in MCI-LB might be partly cholinergically driven. These findings suggest an early cholinergic deficit in MCI-LB.

NEUROIMAGE-CLINICAL (2021)

添加到收藏夹

Article Clinical Neurology

Psychometric Properties of the Clinical Dementia Rating - Sum of Boxes and other Cognitive and Functional Outcomes in a Prodromal Alzheimer's Disease Population

Fiona McDougall et al.

Summary: This study investigated the psychometric properties of commonly used efficacy measures in a clinical trial of prodromal AD. The CDR-SB demonstrated good psychometric properties in prodromal AD, supporting its continued use in clinical trials. There is still room for improvement in assessing functional constructs, and the development of novel measures should continue.

JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE (2021)

添加到收藏夹

Article Psychiatry

Neuroinflammation in dementia with Lewy bodies: a human post-mortem study

Jay Amin et al.

TRANSLATIONAL PSYCHIATRY (2020)

添加到收藏夹

Article Neuroimaging

The combined effect of amyloid-β and tau biomarkers on brain atrophy in dementia with Lewy bodies

Carla Abdelnour et al.

NEUROIMAGE-CLINICAL (2020)

添加到收藏夹

Article Neuroimaging

Topography of cortical thinning in the Lewy body diseases

Rong Ye et al.

NEUROIMAGE-CLINICAL (2020)

添加到收藏夹

Article Neuroimaging

Tau PET and relative cerebral blood flow in dementia with Lewy bodies: A PET study

E. E. Wolters et al.

NEUROIMAGE-CLINICAL (2020)

添加到收藏夹

Article Medicine, General & Internal

Association of Longitudinal β-Amyloid Accumulation Determined by Positron Emission Tomography With Clinical and Cognitive Decline in Adults With Probable Lewy Body Dementia

Zuzana Nedelska et al.

JAMA NETWORK OPEN (2019)

添加到收藏夹

Article Clinical Neurology

Concomitant AD pathology affects clinical manifestation and survival in dementia with Lewy bodies

A. W. Lemstra et al.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2017)

添加到收藏夹

Review Clinical Neurology

Diagnosis and management of dementia with Lewy bodies Fourth consensus report of the DLB Consortium

Ian G. McKeith et al.

NEUROLOGY (2017)

添加到收藏夹

Article Clinical Neurology

Atrophy of the cholinergic basal forebrain in dementia with Lewy bodies and Alzheimer's disease dementia

Michel J. Grothe et al.

JOURNAL OF NEUROLOGY (2014)

添加到收藏夹

Article Rehabilitation

Using the Timed Up & Go Test in a Clinical Setting to Predict Falling in Parkinson's Disease

Joe R. Nocera et al.

ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION (2013)

添加到收藏夹

Article Clinical Neurology

Imaging and acetylcholinesterase inhibitor response in dementia with Lewy bodies

Jonathan Graff-Radford et al.

BRAIN (2012)

添加到收藏夹

Review Clinical Neurology

Differentiating dementia with Lewy bodies and Alzheimer's disease using MRI

Rosie Watson et al.

NEURODEGENERATIVE DISEASE MANAGEMENT (2012)

添加到收藏夹

Article Psychology, Clinical

Sensitivity and Test-Retest Reliability of the International Shopping List Test in Assessing Verbal Learning and Memory in Mild Alzheimer's Disease

Taisia A. C. Thompson et al.

ARCHIVES OF CLINICAL NEUROPSYCHOLOGY (2011)

添加到收藏夹

Article Clinical Neurology

Cholinergic system during the progression of Alzheimer’s disease: therapeutic implications

Elliott J Mufson et al.

Expert Review of Neurotherapeutics (2008)

添加到收藏夹

Article Neurosciences

Hippocampal hypocellularity in the Ts65Dn mouse originates early in development

Hernan A. Lorenzi et al.

BRAIN RESEARCH (2006)

添加到收藏夹

Article Geriatrics & Gerontology

Effectiveness of acetylcholinesterase inhibitors: diagnosis and severity as predictors of response in routine practice

Rohan Van Der Putt et al.

INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY (2006)

添加到收藏夹

Article Neurosciences

Deficits of neuronal density in CA1 and synaptic density in the dentate gyrus, CA3 and CA1, in a mouse model of Down syndrome

MA Kurt et al.

BRAIN RESEARCH (2004)

添加到收藏夹

Review Geriatrics & Gerontology

Pathology and neurotransmitter abnormalities of dementia with Lewy bodies

JE Duda

DEMENTIA AND GERIATRIC COGNITIVE DISORDERS (2004)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.